1 | SPRED1, SPRED2
|
| The negative regulatory Spred1 and Spred2 proteins are required for lens and eye morphogenesis.
|
| Wazin F, Lovicu FJ.
|
| Exp Eye Res. Feb;191:107917. doi: 10.1016/j.exer.2020.107917. Epub 2020 Jan 7. 2020
|
2 | SPRED1, SPRED2
|
| Spred negatively regulates lens growth by modulating epithelial cell proliferation and fiber differentiation.
|
| Susanto A, Zhao G, Wazin F, Feng Y, Rasko JEJ, Bailey CG, Lovicu FJ.
|
| Exp Eye Res 178:160-175. doi: 10.1016/j.exer.2018.09.019. Epub 2018 Oct 2.
2019
|
3 | SPRED1
|
| Spred1 Safeguards Hematopoietic Homeostasis against Diet-Induced Systemic Stress.
|
| Tadokoro Y, Hoshii T, Yamazaki S, Eto K, Ema H, Kobayashi M, Ueno M, Ohta K, Arai Y, Hara E, Harada K, Oshima M, Oshima H, Arai F, Yoshimura A, Nakauchi H, Hirao A.
|
| Cell Stem Cell 22(5):713-725.e8. doi: 10.1016/j.stem.2018.04.002. Epub 2018 Apr 26.
2018
|
4 | NF1, SPRED1
|
| The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation.
|
| Dunzendorfer-Matt T, Mercado EL, Maly K, McCormick F, Scheffzek K.
|
| Proc Natl Acad Sci U S A 113(27):7497-502. doi: 10.1073/pnas.1607298113. Epub 2016 Jun 16.
2016
|
5 | NF1, NFLS, SPRED1
|
| Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
|
| Hirata Y, Brems H, Suzuki M, Kanamori M, Okada M, Morita R, Llano-Rivas I, Ose T, Messiaen L, Legius E, Yoshimura A.
|
| J Biol Chem 291(7):3124-34. doi: 10.1074/jbc.M115.703710. Epub 2015 Dec 3.
2016
|
6 | SPRED1
|
| Spred1, a Suppressor of the Ras-ERK Pathway, Negatively Regulates Expansion and Function of Group 2 Innate Lymphoid Cells.
|
| Suzuki M, Morita R, Hirata Y, Shichita T, Yoshimura A.
|
| J Immunol 195(3):1273-81. doi: 10.4049/jimmunol.1500531. Epub 2015 Jun 26.
2015
|
7 | SPRED1
|
| SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.
|
| Pasmant E, Gilbert-Dussardier B, Petit A, de Laval B, Luscan A, Gruber A, Lapillonne H, Deswarte C, Goussard P, Laurendeau I, Uzan B, Pflumio F, Brizard F, Vabres P, Naguibvena I, Fasola S, Millot F, Porteu F, Vidaud D, Landman-Parker J, Ballerini P.
|
| Oncogene 34(5):631-8. doi: 10.1038/onc.2013.587. Epub 2014 Jan 27.
2015
|
8 | GPM6A, SPRED1, SPRED3, ZDHHC17
|
| The palmitoyl acyltransferase HIP14 shares a high proportion of interactors with huntingtin: implications for a role in the pathogenesis of Huntington's disease.
|
| Butland SL, Sanders SS, Schmidt ME, Riechers SP, Lin DT, Martin DD, Vaid K, Graham RK, Singaraja RR, Wanker EE, Conibear E, Hayden MR.
|
| Hum Mol Genet 23(15):4142-60. doi: 10.1093/hmg/ddu137. Epub 2014 Apr 4.
2014
|
9 | NFLS, SPRED1
|
| Legius syndrome, an Update. Molecular pathology of mutations in SPRED1.
|
| Brems H, Legius E.
|
| Keio J Med 62(4):107-12. Epub 2013 Dec 10. Review.
2013
|
10 | NFLS, SPRED1
|
| Review and update of SPRED1 mutations causing Legius syndrome.
|
| Brems H, Pasmant E, Van Minkelen R, Wimmer K, Upadhyaya M, Legius E, Messiaen L.
|
| Hum Mutat 33(11):1538-46. doi: 10.1002/humu.22152. Epub 2012 Aug 1. Review.
2012
|
11 | DYRK1A, SPRED1, SPRED2
|
| Direct association of Sprouty-related protein with an EVH1 domain (SPRED) 1 or SPRED2 with DYRK1A modifies substrate/kinase interactions.
|
| Li D, Jackson RA, Yusoff P, Guy GR.
|
| J Biol Chem 285(46):35374-85. Epub 2010 Aug 24. 2010
|
12 | NFLS, SPRED1
|
| SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype.
|
| Pasmant E, Sabbagh A, Hanna N, Masliah-Planchon J, Jolly E, Goussard P, Ballerini P, Cartault F, Barbarot S, Landman-Parker J, Soufir N, Parfait B, Vidaud M, Wolkenstein P, Vidaud D, France RN.
|
| J Med Genet 46(7):425-30. Epub 2009 Apr 14.
2009
|
13 | NFLS, SPRED1
|
| SPRED1 mutations (Legius syndrome): another clinically useful genotype for dissecting the neurofibromatosis type 1 phenotype.
|
| Spurlock G, Bennett E, Chuzhanova N, Thomas N, Jim HP, Side L, Davies S, Haan E, Kerr B, Huson SM, Upadhyaya M.
|
| J Med Genet 46(7):431-7. Epub 2009 May 13.
2009
|
14 | NFLS, SPRED1
|
| Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome.
|
| Messiaen L, Yao S, Brems H, Callens T, Sathienkijkanchai A, Denayer E, Spencer E, Arn P, Babovic-Vuksanovic D, Bay C, Bobele G, Cohen BH, Escobar L, Eunpu D, Grebe T, Greenstein R, Hachen R, Irons M, Kronn D, Lemire E, Leppig K, Lim C, McDonald M, Narayanan V, Pearn A, Pedersen R, Powell B, Shapiro LR, Skidmore D, Tegay D, Thiese H, Zackai EH, Vijzelaar R, Taniguchi K, Ayada T, Okamoto F, Yoshimura A, Parret A, Korf B, Legius E.
|
| JAMA 302(19):2111-8.PMID: 19920235 2009
|
15 | SPRED1, TAOK1, TESK1
|
| Spred1 and TESK1--two new interaction partners of the kinase MARKK/TAO1 that link the microtubule and actin cytoskeleton.
|
| Johne C, Matenia D, Li XY, Timm T, Balusamy K, Mandelkow EM.
|
| Mol Biol Cell 19(4):1391-403. Epub 2008 Jan 23. 2008
|
16 | SPRED1, NFLS
|
| Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype.
|
| Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, Somers R, Messiaen L, De Schepper S, Fryns JP, Cools J, Marynen P, Thomas G, Yoshimura A, Legius E.
|
| Nat Genet 39(9):1120-6. Epub 2007 Aug 19. 2007
|
17 | SPRED1
|
| Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors.
|
| Yoshida T, Hisamoto T, Akiba J, Koga H, Nakamura K, Tokunaga Y, Hanada S, Kumemura H, Maeyama M, Harada M, Ogata H, Yano H, Kojiro M, Ueno T, Yoshimura A, Sata M.
|
| Oncogene 25(45):6056-66. Epub 2006 May 1. 2006
|
18 | SPRED1, SPRED2, SPRED3
|
| Spred-2 steady-state levels are regulated by phosphorylation and Cbl-mediated ubiquitination.
|
| Lock P, I ST, Straffon AF, Schieb H, Hovens CM, Stylli SS.
|
| Biochem Biophys Res Commun 351(4):1018-23. Epub 2006 Nov 3.
2006
|
19 | SPRED1, SPRED2
|
| Distinct requirements for the Sprouty domain for functional activity of Spred proteins.
|
| King JA, Straffon AF, D'Abaco GM, Poon CL, I ST, Smith CM, Buchert M, Corcoran NM, Hall NE, Callus BA, Sarcevic B, Martin D, Lock P, Hovens CM.
|
| Biochem J 388(Pt 2):445-54. 2005
|
20 | SPRED1, CAV1
|
| The Sprouty-related protein, Spred-1, localizes in a lipid raft/caveola and inhibits ERK activation in collaboration with caveolin-1.
|
| Nonami A, Taketomi T, Kimura A, Saeki K, Takaki H, Sanada T, Taniguchi K, Harada M, Kato R, Yoshimura A.
|
| Genes Cells 10(9):887-95. 2005
|
21 | SPRED1, SPRED2
|
| The Sprouty-related protein, Spred, inhibits cell motility, metastasis, and Rho-mediated actin reorganization.
|
| Miyoshi K, Wakioka T, Nishinakamura H, Kamio M, Yang L, Inoue M, Hasegawa M, Yonemitsu Y, Komiya S, Yoshimura A.
|
| Oncogene 23(33):5567-76.
2004
|
22 | SPRED1, SPRED2
|
| Spred is a Sprouty-related suppressor of Ras signalling.
|
| Wakioka T, Sasaki A, Kato R, Shouda T, Matsumoto A, Miyoshi K, Tsuneoka M, Komiya S, Baron R, Yoshimura A.
|
| Nature 412(6847):647-51. 2001
|